Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04506554
Title A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fox Chase Cancer Center
Indications

bladder urothelial carcinoma

prostatic urethra urothelial carcinoma

Therapies

Cisplatin + Doxorubicin + Methotrexate + Nivolumab + Vinblastine

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.